NCLT advances Laurus Labs composite scheme, next hearing Sept 10

Scheme filed with the NCLTStrategic Transactions View source PDF Explain this filing

LAURUSLABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+6.6%Reaction day

₹1605.80

prior close

₹1624.80

announcement price

After-mkt

timing

Nifty Midcap 150market+1.1%+5.5% vs market

Pharmaceuticals peers, median of 165sector+0.7%+5.8% vs sector

On the reaction day the stock moved 5.5 pts more than Nifty Midcap 150 and 5.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.6

10m

+2.2

15m

+2.4

30m

+1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+6.6+1.1+5.5+0.7+5.8

Next day

+9.3+1.1+8.2+0.0+9.3

+10.8+1.9+8.9+1.0+9.8

+11.0+1.5+9.4+0.0+11.0

+13.0+2.0+11.0+0.0+13.0

+12.8+3.2+9.6+0.7+12.1

+14.8+3.2+11.6+1.0+13.7

15d

+12.7+3.4+9.3+1.7+11.0

+20.0+3.6+16.4+1.9+18.1

+25.2-2.7+27.9+2.1+23.1

+33.4-7.4+40.8-3.1+36.5

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Laurus Labs informed exchanges that NCLT has directed petitioner companies to serve hearing notice in Form CAA-3 to regulators for the composite scheme of arrangement. The scheme involves demerger of Unit-1 of wholly-owned subsidiary Laurus Synthesis into another wholly-owned subsidiary Sriam Labs, and amalgamation of the remaining LSPL with Laurus Labs. Next hearing is September 10, 2026. Since all entities are wholly-owned, this is internal restructuring.

Likely market impact

Internal restructuring between wholly-owned subsidiaries; no immediate impact on minority shareholders. NCLT progress is a procedural positive.